Gilead Sciences, Inc. (GILD) NASDAQ

130.50

-0.19(-0.15%)

Updated at May 21 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Daniel O'Day	Chairman & Chief Executive Officer	8.7M	1965
Andrew D. Dickinson	Chief Financial Officer	3.14M	1970
Johanna Mercier	Chief Commercial & Corporate Affairs Officer	3.44M	1970
Dietmar Berger	Chief Medical Officer	5.92M	1969
See-Chun Phan	Vice President of Clinical Research Oncology	0	1964
Flavius Martin	Executive Vice President of Research	0	N/A
Linda Slanec Higgins	Senior Vice President of Research, Innovation & Portfolio	0	1962
Jackson Egen	Vice President of Research Oncology	0	N/A
Bernard Fine	Vice President of Oncology & Franchise Head of Early Development	0	N/A
Erin Burkhart	Senior VP, Controller & Principal Accounting Officer	0	1979
Jacquie Ross	Senior Vice President of Treasury and Investor Relations	0	N/A
Janet Dorling	Senior Vice President of Intercontinental Region & Global Patient Solutions	0	1975
Jyoti K. Mehra	Executive Vice President of Human Resources	0	1977
Keeley Wettan	Executive VP and General Counsel of Legal & Compliance	0	1975
Bilal Piperdi	Vice President of Clinical Research Oncology	0	N/A

Name

Title

Pay

Year Born

Daniel O'Day

Chairman & Chief Executive Officer

8.7M

1965

Andrew D. Dickinson

Chief Financial Officer

3.14M

1970

Johanna Mercier

Chief Commercial & Corporate Affairs Officer

3.44M

1970

Dietmar Berger

Chief Medical Officer

5.92M

1969

See-Chun Phan

Vice President of Clinical Research Oncology

1964

Flavius Martin

Executive Vice President of Research

N/A

Linda Slanec Higgins

Senior Vice President of Research, Innovation & Portfolio

1962

Jackson Egen

Vice President of Research Oncology

N/A

Bernard Fine

Vice President of Oncology & Franchise Head of Early Development

N/A

Erin Burkhart

Senior VP, Controller & Principal Accounting Officer

1979

Jacquie Ross

Senior Vice President of Treasury and Investor Relations

N/A

Janet Dorling

Senior Vice President of Intercontinental Region & Global Patient Solutions

1975

Jyoti K. Mehra

Executive Vice President of Human Resources

1977

Keeley Wettan

Executive VP and General Counsel of Legal & Compliance

1975

Bilal Piperdi

Vice President of Clinical Research Oncology

N/A

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.